Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disordersSCIENCE TRANSLATIONAL MEDICINEIF14.62024-01-179PRE
A functional screen for Myc-responsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolismMOLECULAR AND CELLULAR BIOLOGYIF2.72023-04-01197OA
Activation of Rho-dependent cell spreading and focal adhesion biogenesis by the v-Crk adaptor proteinMOLECULAR AND CELLULAR BIOLOGYIF2.72023-03-2868OAAI
TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteinsMOLECULAR AND CELLULAR BIOLOGYIF2.72023-03-27139OAAI
A conserved Myc protein domain, MBIV, regulates DNA binding, apoptosis, transformation, an G2 arrestMOLECULAR AND CELLULAR BIOLOGYIF2.72023-03-27112OAAI
Small molecule inhibition of glycogen synthase 1 restores autophagolysosomal and metabolic pathway dysfunction in a mouse model of Pompe diseaseMOLECULAR GENETICS AND METABOLISMIF3.52023-02-010PRE
Quantification of peripheral blood mononuclear cell (PBMC) glycogen as a novel biomarker for therapeutic intervention in Pompe diseaseMOLECULAR GENETICS AND METABOLISMIF3.52023-02-010PRE
Pharmacology of small molecule inhibitors of GYS1 in a mouse model of Pompe diseaseMOLECULAR GENETICS AND METABOLISMIF3.52022-02-011PRE
Substrate reduction therapy for Pompe disease: Small molecule inhibition of glycogen synthase 1 in preclinical modelsMOLECULAR GENETICS AND METABOLISMIF3.52022-02-010PRE
Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitorSCIENTIFIC REPORTSIF3.92021-07-1416OAAI
Neurofilament light is a treatment-responsive biomarker in CLN2 diseaseANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGYIF3.92019-12-0821OAAI
CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosisTHORAXIF7.72017-03-0146OAAI
Development of an electrochemiluminescent assay to measure LAMP2 in canine cerebrospinal fluid samplesMOLECULAR GENETICS AND METABOLISMIF3.52017-01-010PREAI
TARGET AND BIOMARKER DISCOVERY FOR HEDGEHOG PATHWAY ACTIVITY IN IDIOPATHIC PULMONARY FIBROSIS IN SUPPORT OF A PHASE 2 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF VISMODEGIB IN IPF (ISLAND)THORAXIF7.72014-11-100OAAI
Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosisTHORAXIF7.72014-09-12215OAAI
Endogenously Expressed IL-13Rα2 Attenuates IL-13-Mediated Responses but Does Not Activate Signaling in Human Lung FibroblastsJOURNAL OF IMMUNOLOGYIF3.42014-07-0162OAAI
Identification of a previously undescribed divergent virus from the Flaviviridae family in an outbreak of equine serum hepatitisPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.12013-03-18127OA
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition三阴性乳腺癌中MYC途径的激活与CDK抑制是合成致死的JOURNAL OF EXPERIMENTAL MEDICINEIF10.62012-03-19312OAAI
Synthetic-Lethality of Triple-Negative Breast Cancers Via the MYC Oncogene PathwayCANCER RESEARCHIF16.62010-12-010PRE
The Lytic Transcriptome of Kaposi's Sarcoma-Associated Herpesvirus Reveals Extensive Transcription of Noncoding Regions, Including Regions Antisense to Important GenesJOURNAL OF VIROLOGYIF3.82010-08-1576OAAI